Search results
Showing 166 to 180 of 963 results for death
In development Reference number: GID-HTE10067 Expected publication date: 19 May 2026
Roflumilast for treating chronic obstructive pulmonary disease (TA461)
Evidence-based recommendations on roflumilast (Daxas) for treating chronic obstructive pulmonary disease in adults with chronic bronchitis.
consequences, and the need for shunt insertion. Outcomes should include death and disability in the long-term: these should be reported...
Pre-hospital initiation of fluid replacement therapy in trauma (TA74)
Evidence-based recommendations on giving intravenous (IV) fluid replacement therapy for people with serious injuries before reaching hospital.
a diagnosis of COVID-19) at increased risk of severe COVID-19 illness or death? Any explanatory notes(if applicable) It is recommended...
Evidence-based recommendations on isatuximab (Sarclisa) plus bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma in adults when an autologous stem cell transplant is unsuitable.
Show all sections
Summary of the evidence on cangrelor for coronary revascularisation to inform local NHS planning and decision-making
In development Reference number: GID-HTE10065 Expected publication date: 02 April 2026
Carotid artery stent placement for symptomatic extracranial carotid stenosis (IPG389)
Evidence-based recommendations on carotid artery stent placement for symptomatic extracranial carotid stenosis. This involves using a metal mesh called a stent to widen the narrowed carotid artery.
View recommendations for IPG389Show all sections
Sections for IPG389
Evidence-based recommendations on pembrolizumab (Keytruda) with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer (NSCLC) in adults whose tumours have no epidermal growth factor receptor (EGFR)- or anaplastic lymphoma kinase (ALK)-positive mutations.
Ponesimod for treating relapsing–remitting multiple sclerosis (TA767)
Evidence-based recommendations on ponesimod (Ponvory) for treating relapsing–remitting multiple sclerosis in adults.
Lipid disorders: FH assessment and diagnosis (historical readings) (IND260)
This indicator covers the percentage of patients with a total cholesterol reading greater than 7.5 mmol/litre when aged 29 years or under, or greater than 9.0 mmol/litre when aged 30 years or over, who have been: diagnosed with secondary hyperlipidaemia, or clinically assessed for familial hypercholesterolaemia, or referred for assessment for familial hypercholesterolaemia, or genetically diagnosed with familial hypercholesterolaemia. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM244
Integrated health and social care for people experiencing homelessness (NG214)
This guideline covers providing integrated health and social care services for people experiencing homelessness. It aims to improve access to and engagement with health and social care, and ensure care is coordinated across different services.
This guideline covers assessing and managing motor neurone disease (MND). It aims to improve care from the time of diagnosis, and covers information and support, organisation of care, managing symptoms and preparing for end of life care.
ID NG106/5 Question Risk tools for predicting non-sudden death in heart failure:- What is the most accurate prognostic risk tool in...